BioVentures

Apex Bioventures Acquisition Corp. Sets Date for Special Meeting of Stockholders to Approve Dissolution

HILLSBOROUGH, Calif., May 7 /PRNewswire-FirstCall/ -- Apex Bioventures Acquisition Corporation (NYSE Amex: PEX ) ("Apex") announced today that a special meeting of stockholders will be held at 10:00 a.m. local time on Tuesday, June 2, 2009, at the offices of Mintz Levin Cohn Ferris Glovsky &...

Apex Bioventures Acquisition Corp. To Seek Stockholder Approval To Liquidate and Dissolve

HILLSBOROUGH, Calif., March 5 /PRNewswire-FirstCall/ -- Apex Bioventures Acquisition Corporation (NYSE Alternext US: PEX) ("Apex") announced today that its board of directors has determined that Apex will not consummate a business combination in the time frame required by its Second Amended and Re...

Rcadia Medical Imaging Closes $3.3 Million Investment Led by BioVentures Investors

BOSTON, Dec. 15 /PRNewswire/ -- Rcadia Medical Imaging, Ltd., developer of the COR Analyzer(TM) software for the automated analysis of coronary CT angiography (CCTA) studies, has closed a $3.3M investment round led by BioVentures Investors of Cambridge, MA, Rcadia announced today. Existing investo...

Apex Bioventures Announces Trust Investment Details

HILLSBOROUGH, Calif., Oct. 14 /PRNewswire-FirstCall/ -- In light of recent events impacting the global financial markets, Apex Bioventures Acquisition Corp. (Amex: PEX ), a publicly traded special purpose acquisition company with healthcare industry expertise, announced today details related ...

Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies

FRANKLIN, Mass., April 21 /PRNewswire-FirstCall/ -- Echo Therapeutics (OTC Bulletin Board: ECTE) today announced that it has signed a dermatology product and transdermal drug delivery technology right of first offer agreement with Cato BioVentures, the venture capital affiliate of Cato Researc...

Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics

... Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT bioventures and Sofinnova Ventures. For more information, please visit www.catbio.com . Catalyst Biosciences, Inc. Erik Wiberg +1.650.266.865...

Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products

... Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT bioventures and Sofinnova Ventures. For more information, please visit www.catbio.com . About Wyeth Pharmaceuticals Wyeth Pharmaceuticals, a division...

Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease

...001. The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, Inc. (Nasdaq: CEGE ) as well as Hamilton bioventures and California Technology Partners. Contacts: Jeffrey M. Ostrove, Ph.D. President and CEO Ceregene, Inc. ...

SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results

...tic that we will be able to reach agreement with suitable partner(s) to commercialize these products. We recently announced that we retained HealthPro bioventures LLC ("HealthPro"), a life science investment bank and strategic advisory firm, to assist us in our partnership activities. We continue to be very enc...

SCOLR Pharma, Inc. Announces Engagement of HealthPro as Financial Advisor

... BOTHELL, Wash., April 2 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today announced the engagement of HealthPro bioventures LLC ("HealthPro"), a life sciences investment bank and strategic advisory firm, as its financial advisor in connection with the evaluation of various ...

BioVentures in Medical Technology

Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures

Phase 3 clinical oversight and regulatory services for Cordex's ATPace arrhythmia drug to be provided by Cato Research LA JOLLA, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has entered into a long-term strategic master servi...

S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis

...team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Aravis Venture, Novartis bioventures and other international funds. More information about S*BIO can be found at www.sbio.com . S*BIO Pte Ltd: Stephen Keith Rhind, Ph...

S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies

...cal development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Novartis bioventures and other international funds. More information about S*BIO can be found at http://www.sbio.com . S*BIO Pte Ltd: Stephen Keith Rhind, Ph.D. Sen...

Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic

...ounced today a strategic equity investment by Cato bioventures and a collaboration with Cato Research Ltd., its g....abeomecorp.com . About Cato BioVentures Cato bioventures is the venture capital affiliate of Cato Research ...ic CRO service agreements with Cato Research, Cato bioventures invests its in-kind CRO Service Capital(TM) in inn...

Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema

... Nordic Biotech II K/S and MPM bioventures close on additional $6 million investment on top of $75 million previous investment AMSTERDAM, Netherlands and ALAMEDA, Calif., Feb. 28 /PR...

Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease

...nesys, Inc. (Nasdaq: CEGE ). The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys as well as Hamilton bioventures and California Technology Partners. ...

Preclinical Data on Cytogen's Technology to be Reported at the AACR Annual Meeting

... and external research collaborations, Cytogen is exploring strategic transactions for AxCell BioSciences and will be presenting at the 9th Annual C21 bioventures Conference (C21) taking place in Monterey, California May 22-24, 2007. -0- Additional details for the AACR presentations are as follows: Pre...

Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinson's Patients

...red in South San Francisco, CA. Ceregene's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, as well as Hamilton bioventures and, California Technology Partners. About The Michael J. Fox Foundation Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research i...

Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease

...red in South San Francisco, CA. Ceregene's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, as well as Hamilton bioventures and, California Technology Partners. Contact: Jeffrey M. Ostrove, Ph.D. President and CEO Ceregene, Inc. (858) 458-880...

Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database

...xternal research collaborations, Cytogen is exploring strategic transactions for AxCell BioSciences and will be presenting today at the 9th Annual C21 bioventures Conference (C21) taking place in Monterey, California. About ProChart(TM) ProChart is a proprietary, comprehensive, experimentally validated datab...

BioVentures in Biological Technology

Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex

HILLSBOROUGH, Calif., May 11 /PRNewswire-FirstCall/ -- Apex Bioventures Acquisition Corporation (NYSE Amex: PEX ) (the "Company") announced today that it has received notice from NYSE Amex LLC (the "Exchange") that the plan of compliance submitted by the Company has been accepted by the Exchange...

Newbridge Securities Corporation Forms BioVentures Division

Newbridge Expands its Presence in the Biotech Industry FT. LAUDERDALE, Fla., Feb. 17 /PRNewswire/ -- Newbridge Securities Corporation ("Newbridge"), a full-service securities broker-dealer and investment bank, is proud to announce the formation of the Newbridge BioVentures Division ("NBV"). N...

Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)

- Agreement includes upfront, milestone and royalty payments on future sales - TORONTO, April 8 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company dedicated to the research and development of pharmaceuti...

Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

...001. The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, Inc. (Nasdaq: CEGE ) as well as Hamilton bioventures and California Technology Partners. ...

Intellikine Completes $51 Million Financing

... the treatment of cancer, inflammation and autoimmune diseases, announced today that it has raised $51 million in preferred stock financing. Novartis bioventures Ltd. led the financing in which additional new investors U.S. Venture Partners, Biogen Idec and FinTech Global Capital participated. Markus Goebel, M...

NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business

...ral Gas, in the United States in consideration for a controlling stake in NexGen and (ii) the purchase of NexGen's holdings in its subsidiaries by Mac bioventures in consideration for a part of the debt it's assuming in NexGen. The Letter of Intent further contemplates that the number of shares up to 65 m...

Accera, Inc. to Present at Upcoming Investor Conferences

...O Venture Conference on April 1 at 10:15 a.m. EDT at the Sheraton Boston Hotel in Boston, MA. On April 9 at 11:30 a.m. PDT, he will present at the C21 bioventures Conference at the Meritage Resort in Napa Valley, CA. In early March, the company launched Axona(TM), a medical food available only by prescripti...

Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development

... Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT bioventures and Sofinnova Ventures. For more information, please visit www.catbio.com . Catalyst Biosciences, Inc. Erik Wiberg Chief Financial...

S*BIO Receives BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award

...dical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis bioventures and other international funds. More information about S*BIO can be found at www.sbio.com . S*BIO Pte Ltd: Russo Partner...

Sopherion Therapeutics Secures $55 Million in Series C Funding

...toxicity while preserving antitumor efficacy. In January 2008, Zoticon bioventures in-licensed Myocet and provided funding of $20 million to Sopherion and sub...merica. For more information, visit www.sopherion.com . About Zoticon bioventures Zoticon is a privately held global drug development and healthcare inv...

BioVentures in Biological Products

BioTracker Dye 1ml from BioVentures

Description: "BioTracker 6X Bromophenol Blue Tracking Dye is composed of 60% St DI H2O, 30% Glycerol, 10% 10XTE, 0.25% BPB Dye and 0.85% SDS....
Company:BioVentures